Sanofi $SNY Shares Sold by US Bancorp DE

Key Points

• US Bancorp DE reduced its stake in Sanofi by 11.3%, owning 101,509 shares after selling 12,979 shares during the second quarter, with holdings valued at $4.9 million.
• Sanofi's shares have received positive analyst ratings, with JPMorgan Chase upgrading from "neutral" to "overweight" and an average price target set at $62.67.
• The company reported a decrease in earnings per share to $0.90 for the last quarter, missing estimates by $0.06, while revenue was $11.34 billion, surpassing analyst expectations.

US Bancorp DE cut its stake in Sanofi (NASDAQ:SNY - Free Report) by 11.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 101,509 shares of the company's stock after selling 12,979 shares during the period. US Bancorp DE's holdings in Sanofi were worth $4,904,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its stake in Sanofi by 1.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,036,878 shares of the company's stock valued at $612,106,000 after acquiring an additional 193,196 shares during the period. Federated Hermes Inc. lifted its stake in Sanofi by 58.5% during the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock valued at $218,933,000 after acquiring an additional 1,456,269 shares during the period. Envestnet Asset Management Inc. lifted its stake in Sanofi by 6.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company's stock valued at $181,764,000 after acquiring an additional 211,641 shares during the period. Raymond James Financial Inc. lifted its stake in Sanofi by 15.1% during the 1st quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company's stock valued at $179,914,000 after acquiring an additional 425,597 shares during the period. Finally, Nuveen LLC acquired a new stake in Sanofi during the 1st quarter valued at approximately $177,831,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on SNY. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Morgan Stanley raised shares of Sanofi from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $56.00 to $58.00 in a report on Monday, September 8th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "hold" rating to a "buy" rating in a report on Tuesday, September 2nd. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Sanofi in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $62.67.

Sanofi Stock Performance

NASDAQ:SNY opened at $48.80 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The company has a fifty day moving average of $48.29 and a two-hundred day moving average of $49.70. The stock has a market capitalization of $119.83 billion, a PE ratio of 11.73, a P/E/G ratio of 1.17 and a beta of 0.51. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The company had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business's revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.73 earnings per share. As a group, research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.